Cite
HARVARD Citation
Kolkhof, P. et al. (n.d.). Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage. European heart journal. p. . [Online].